First look: can a new drug candidate pass early safety tests in humans?

NCT ID NCT07736638

Recruiting now Knowledge-focused Sponsor: AbbVie Source: ClinicalTrials.gov ↗

First seen Jul 30, 2026 · Last updated Aug 04, 2026 · Updated 3 times

Summary

This early-stage trial is testing a single dose of an experimental drug called ABBV-859 in 64 healthy adults. The goal is to see how the body processes the drug, whether it causes side effects, and whether the immune system reacts to it. Participants receive either the drug or a placebo, given as a pill or through an IV. No therapeutic benefit is expected — the study is purely about safety and basic drug behavior.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: an experimental drug called ABBV-859, given as an oral tablet or intravenous infusion
What could go wrong: This is a very early, first-in-human trial with only 64 healthy volunteers. The drug may cause unexpected side effects and may never be developed further.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY VOLUNTEER

Contacts and locations

Locations

Acpru /Id# 284029
RECRUITING

Grayslake, Illinois, 60030, United States
CenExel ACT- Anaheim Clinical Trials /ID# 284382
RECRUITING

Anaheim, California, 92801, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.